Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.01Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: 18.59%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
BioCryst demonstrated strong financial performance in the first quarter of 2025, with record revenue growth and accelerated profitability. The company successfully reduced its debt and made notable progress in its pipeline, particularly with the pediatric NDA submission for ORLADEYO. While there are challenges in patient recruitment for new programs, the overall sentiment is positive due to the company's financial strength and strategic advancements.Company Guidance
During the BioCryst First Quarter 2025 Earnings Conference Call, the company provided updated guidance, highlighting strong performance and financial improvements. The U.S. commercial team significantly advanced the transition of patients on ORLADEYO from free drug to paid status, leading to quarterly revenue of $134 million. This success prompted BioCryst to raise its annual revenue guidance for ORLADEYO to between $580 million and $600 million, reflecting a growth rate of 33% to 37% over the previous year. The improved revenue growth has increased the company's margins and accelerated its profitability goal, with expectations to be profitable on a full-year basis in 2025. BioCryst's enhanced financial strength allowed it to pay down $75 million of its debt in April. Additionally, ORLADEYO has reached a revenue level where the company no longer pays a royalty on sales above $550 million, moving closer to its peak sales target of $1 billion.Strong Revenue Growth
BioCryst reported quarterly revenue of $134 million, leading to an increased annual revenue guidance for ORLADEYO to between $580 million and $600 million, reflecting 33% to 37% growth over the previous year.
Accelerated Profitability
The company now expects to be profitable on a full-year basis in 2025, a year earlier than previously planned, due to increased financial strength and improved cash flow.
Successful Debt Reduction
BioCryst paid down $75 million of its debt in April, reducing outstanding debt to $249 million and saving approximately $23 million in interest payments over the life of the debt.
Pediatric NDA Submission for ORLADEYO
The company submitted a pediatric NDA for ORLADEYO, introducing an oral granule formulation for younger patients, aiming to be the first targeted oral prophylactic therapy for children aged two to eleven.
High Patient Satisfaction and Preference
A recent patient survey indicated that 70% of U.S. HAE patients strongly prefer oral prophylaxis, up from 51% in 2023, suggesting increased satisfaction with ORLADEYO.
Pipeline Progress
BioCryst received authorization to initiate patient enrollment for BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema, with clinical data expected by the end of the year.
BCRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | $8.93 | $11.03 | +23.52% |
Feb 24, 2025 | $9.21 | $8.29 | -9.99% |
Nov 04, 2024 | $8.43 | $7.35 | -12.81% |
Aug 05, 2024 | $7.02 | $7.51 | +6.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biocryst Pharmaceuticals (BCRX) report earnings?
Biocryst Pharmaceuticals (BCRX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Biocryst Pharmaceuticals (BCRX) earnings time?
Biocryst Pharmaceuticals (BCRX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCRX EPS forecast?
BCRX EPS forecast for the fiscal quarter 2025 (Q2) is 0.01.
